Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Over 4 Years of Safety and Efficacy with Voxelotor Treatment for Patients with Sickle Cell Disease: Updated Results from an Open-Label Extension of the Phase 3 HOPE Trial

Maureen Okam Achebe, Hoda MA Hassab, Salam Al-Kindi, Clark Brown, Paul Telfer, Bart J. Biemond, Thokozeni Lipato, Mark Davis, Sarah Gray, Victor R. Gordeuk

Blood (2023) 142 (Supplement 1): 2527.

https://doi.org/10.1182/blood-2023-188616

Published: 2023

Journal Articles

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Blood (2022) 140 (Supplement 1): 1498–1500.

https://doi.org/10.1182/blood-2022-159993

Published: 2022

Journal Articles

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Murtadha Al-Khabori, MD, Shoaib Al-Zadjali, PhD, Iman Al Noumani, Khalil Al Farsi, Salam Al-Kindi, MD, Mohamed Al Huneini, MD, Naglaa Fawaz, MBBChir, MMSc, PhD, Al Lamki Sulayma, MD, Mahdiya Pir Al Bulushi, MD FRCPC, Khalid Al Hashmi, MD, Muna Al Tarshi, MD, Muhanna Almusalhi

Blood (2019) 134 (Supplement_1): 5383.

https://doi.org/10.1182/blood-2019-128309

Published: 2019

Journal Articles

Impact of Human Leukocyte Antigen on the Risk of Stroke in Patients with Sickle Cell Disease

Huda Al-Harrasi, MD, Murtadha Al-Khabori, MD, Salam Al-Kindi, MD, Yasser Ahmed Mohamed Soliman Wali, MD, Mohamed Al Huneini, MD, Hamad Al-Riyami, PhD

Blood (2019) 134 (Supplement_1): 4831.

https://doi.org/10.1182/blood-2019-125038

Published: 2019

Journal Articles

The Optimal Cut-Off Level for Hemoglobin A2 to Differentiate between Sickle Cell Disease Genotypes

Fayiz Al Shueili, MD, Murtadha K. Al-Khabori, BSc,MD FRCPC, MSc, Salam Al-Kindi, Yasser Wali, MD, Shoaib Al-Zadjali, PhD

Blood (2018) 132 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2018-99-118697

Published: 2018

Journal Articles

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Blood (2018) 132 (Supplement 1): 505.

https://doi.org/10.1182/blood-2018-99-118508

Published: 2018

Journal Articles

Incorporation of Clinical Information to Decipher Driver Mutations in Myeloproliferative Neoplasms

Murtadha K. Al-Khabori, BSc, MD FRCPC,MSc, Shoaib Al-Zadjali, PhD, Mohamed Al-Rawahi, BSc, Iman Al Noumani, Khalil Al Farsi, Salam Al-Kindi, Mohamed Al Huneini, Al Lamki Sulayma, MD, Mahdiya Al-Belushi, MD, Khalid Al Hashmi, MD, Muna Al Tarshi, MD, Muhanna Almusalhi

Blood (2018) 132 (Supplement 1): 5489.

https://doi.org/10.1182/blood-2018-99-118546

Published: 2018

Journal Articles

Sickle Cell Disease Patients with Systemic Lupus Erythematosus Exhibit Quantitative and Qualitative Impairments in Circulating B Regulatory Cells

Amal Al-Naamani, Ahmed Al-Yarabi, Nasser Ambu-Ali, Tahar Al-Shabibi, Zahra Al-Qarni, Nasra Al-Obaidani, Hamad Khan, Juma K Al-Kaabi, Jalila Al-Shekaili, Amar Oukil, Sulaiman Ali Al-Hashmi, Alya Al-Ansari, Fahad Al-Zadjali, Murtadha K. Al-Khabori, BSc, MD FRCPC, ABIM, M.Sc, CIP, Khalil Al-Farsi, MD, Mohammed N. Alhuneini, MD BSc, FRCP, Yasser Wali, Salam Al-Kindi, Mohamed-Rachid Boulassel, DEMS, PhD

Blood (2016) 128 (22): 3641.

https://doi.org/10.1182/blood.V128.22.3641.3641

Published: 2016

Journal Articles

Influence of Genetic Modifiers on Levels of Invariant Natural Killer T-Cells in Patients with Sickle Cell Anemia

Ahmed Al-Yarabi, Tahar Al-Shabibi, Nasser Ambu-Ali, Shoaib Al-Zadjali, Abeer Al-Zubaidi, Murtadha K. Al-Khabori, BSc, MD FRCPC, ABIM, M.Sc, CIP, Mohammed Al-Huneini, Salam Al-Kindi, Yasser Wali, Mohamed-Rachid Boulassel, DEMS, PhD

Blood (2016) 128 (22): 4843.

https://doi.org/10.1182/blood.V128.22.4843.4843

Published: 2016

Journal Articles

Circulating Invariant Natural Killer T Cell Subsets Are Functionally Preserved in Splenectomized Children with Sickle Cell Disease Compared to Patients with Large Spleen

Mohamed-Rachid Boulassel, DEMS, PhD, Abeer Al-Zubaidi, Ismail Beshlawi, Zahra Al-Qarni, Nidaa Al-Naamany, Shoaib Al-Zadjali, Sulaiman Al-Hashmi, Hamad Khan, Mohammed Al Huneini, Khalil Al Farsi, Murtadha K. Al-Khabori, BSc, MD FRCPC, ABIM, M.Sc, CIP, Salam Al-Kindi, Yasser Wali

Blood (2015) 126 (23): 3389.

https://doi.org/10.1182/blood.V126.23.3389.3389

Published: 2015

Journal Articles

Permanent Alopecia in Children Following Busulfan Based Conditioning Is Associated with Glutathione M1 Null Genotype.

J. David Dennison, S. Muralitharan, Melanie Tauro, Shoaib Zadjali, Salam Al Kindi, Maria Lourdes Macalalad, Anil Pathare, Krishnaratnam Kannan, Aqueela Taqi Al Lawatia, R. Krishnamoorthy, Shyam Sunder Ganguly

Blood (2005) 106 (11): 2740.

https://doi.org/10.1182/blood.V106.11.2740.2740

Published: 2005

Journal Articles

Suboptimal Busulphan Exposure Is Associated with Mixed Hematopoietic Chimerism, a Risk Factor for Rejection in Bone Marrow Transplantation for Homozygous beta Thalassemia.

J. David Dennison, MD, Shoaib Al Zadjali, Melanie Tauro, Salam Al Kindi, MD, S. Muralitharan, Krishnaratnam Kanan, MD, Shahina Daar, MD, Anil Pathare, MD, Marie-Helene Quernin, Evelyne Jacqz-Aigrain, MD, R. Krishnamoorthy, MD, Shyam Sundar Ganguly, MD

Blood (2004) 104 (11): 1149.

https://doi.org/10.1182/blood.V104.11.1149.1149

Published: 2004

Journal Articles

Efficient Iron Chelation Resulting in Improved Myocardial Performance with Combined Desferrioxamine and Deferiprone in Beta Thalassemia Major Patients.

Anil V. Pathare, MD, Shahina Daar, MD, Salam Al Kindi, MD, J. David Dennison, MD

Blood (2004) 104 (11): 3766.

https://doi.org/10.1182/blood.V104.11.3766.3766

Published: 2004

NARROW

Over 4 Years of Safety and Efficacy with Voxelotor Treatment for Patients with Sickle Cell Disease: Updated Results from an Open-Label Extension of the Phase 3 HOPE Trial

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Impact of Human Leukocyte Antigen on the Risk of Stroke in Patients with Sickle Cell Disease

The Optimal Cut-Off Level for Hemoglobin A2 to Differentiate between Sickle Cell Disease Genotypes

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Incorporation of Clinical Information to Decipher Driver Mutations in Myeloproliferative Neoplasms

Sickle Cell Disease Patients with Systemic Lupus Erythematosus Exhibit Quantitative and Qualitative Impairments in Circulating B Regulatory Cells

Influence of Genetic Modifiers on Levels of Invariant Natural Killer T-Cells in Patients with Sickle Cell Anemia

Circulating Invariant Natural Killer T Cell Subsets Are Functionally Preserved in Splenectomized Children with Sickle Cell Disease Compared to Patients with Large Spleen

Permanent Alopecia in Children Following Busulfan Based Conditioning Is Associated with Glutathione M1 Null Genotype.

Suboptimal Busulphan Exposure Is Associated with Mixed Hematopoietic Chimerism, a Risk Factor for Rejection in Bone Marrow Transplantation for Homozygous beta Thalassemia.

Efficient Iron Chelation Resulting in Improved Myocardial Performance with Combined Desferrioxamine and Deferiprone in Beta Thalassemia Major Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only